Articles > New & Newsworthy

Woman showing another woman data on her smartphone about health and exercise.

The T1D Exchange Registry launched last year, and it’s begun to provide a fascinating and vital look into some of the more detailed aspects of life with type 1 diabetes. From your age of diagnosis to frequency of testing, we’ve learned more about how you’re living, working, and caring for diabetes across the country.

Recent studies have re-opened the long-running conversation about the cost-effectiveness and benefits of diabetes safety alert dogs. At up to $25,000 - how useful are they?

Data security is paramount for health registry databases

Today, January 28th, has been designated by the Council of Europe as Data Privacy and Protection Day since 2007, and recognized two years later by the U.S. Congress in 2009.

Executives of the Big Three pharma companies involved in diabetes research, development, and manufacturing — Eli Lilly and Co., Novo Nordisk, and Sanofi — spoke publicly this week at JPMorgan’s 2020 Healthcare conference on issues related to insulin pricing and supply.

Tandem t:slim X 2 pump with control IQ technology

Last month, the FDA approved the Tandem Diabetes Care update to its t:slim X2 insulin pump Control-IQ technology, clearing the way for the first automated and interoperable insulin dosing system on the U.S. market.

Fiasp fast acting insulin pen

The U.S. Food and Drug Administration has approved Novo Nordisk's fast-acting Fiasp insulin for use in children as well as adults, the pharmaceutical firm announced Monday.

A patient loads insulin for his routine shot.

At least 17 states have passed laws carving out exceptions for pharmacists to fill insulin prescriptions during emergency situations. These legal reforms are seen by some advocates as the first real sign of progress for improved access to insulin in the United States.

logo for French pharma manufacturer Sanofi

Sanofi, the French pharmaceutical giant which manufactures the long-acting insulin Lantus, announced Monday that it would no longer be investing in research for new drugs to treat diabetes. The manufacturer also told investors it would no longer be investigating new treatments for cardiovascular health. “To be out of cardiovascular and diabetes is not easy for …

Two airline pilots monitoring instruments

The FAA is moving to allow pilots with type 1 diabetes to take command of U.S.-based commercial flights, reports CNN.

Omnipod with app.

Insulet will now be able to market their continuous insulin delivery system as an integrated insulin pump.